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Abstract: Amylin, (islet amyloid polypeptide) or diabetes-associated peptide is co-secreted with insulin in the islet of 
Langerhans of diabetic patients in approximately 1:100, amylin-insulin ratio. The soluble form of amylin, an analogue of 
amylin, is used as a supplement to insulin in the treatment of type 1 diabetes. Co-administration of amylin analogue with 
insulin to patients with type 1 diabetes induced a larger reduction in proprandial hyperglycemia, with a concomitant re-
duction in the level of glucagon when compared to insulin monotherapy. The actions of amylin analogues appear to be 
synergistic to insulin, with which it is co-released from insulin-producing beta cells after a meal. Amylin analogues such 
as pramlintide has been shown to significantly reduce
 body weight, HbA1c values and even the dosage of insulin.
  A mod-
erate weight loss can also be achieved in obese patients with or without diabetes. A major side effect of some amylin ana-
logues includes nausea and excitation of the area postrema. This review examines the medicinal chemistry of amylin and 
its analogues and their effects. 
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INTRODUCTION 
  Diabetes mellitus continues to pose a significant burden 
on healthcare services worldwide because of its high preva-
lence. Different management protocols, including diet modi-
fication, lifestyle changes, therapeutic regimens have been 
developed to reduce the signs and symptoms, and hence the 
severity of diabetes mellitus. Attention has been focused on 
several bioactive agents that are capable of increasing insulin 
release especially in type 1 diabetes. One of such agents is 
amylin. Amylin, also called IAPP (islet amyloid polypep-
tide) or diabetes-associated peptide, is produced by pancre-
atic beta cell and co-secreted with insulin. It occurs in the 
islet of Langerhans of diabetic patients in approximately 
1:100 amylin- insulin ratio. It has long been reported that 
amylin, like amylin beta, known to be associated with Alz-
heimer’s disease, can induce apoptosis in pancreatic beta cell 
[1,2]. Amylin was discovered in human in 1987 by Cooper et 
al [3] and in cats by Westermark et al. [4]  
STRUCTURE OF AMYLIN 
  Amylin is an insoluble protein with a relatively low tis-
sue concentration. Amylin forms long stable fibres which are 
arranged in regular pattern [5]. It is a small peptide with a 
molecular weight of only 3.9 kDa [1, 2]. Its amino acid se-
quence is 46% identical to that of human beta-CGRP (calci-
tonin-gene related peptide). The ability of amylin to destroy  
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pancreatic beta cell appears to be species specific. For exam-
ple rat and mice amylin have 3 proline substitutions at amino 
acid positions 25, 28 and 29. These substitutions have been 
reported to prevent the development of the fibrillary form of 
amyloid. The inability of this type of amylin to destroy pan-
creatic beta cells have been used to development a human 
amylin analogue capable of stimulating insulin release. 
MEDICINAL CHEMISTRY OF AMYLIN 
  Human amylin has a disulfide bond between cysteine   
residues 2 and 7. The amidated C-terminal and the disulfide  
bond must be intact in order for amylin or its analogues to be  
biologically active [6]. The amino acid sequences of amylin  
and its analogue (pramlintide) are shown in (Figs. 1, 2).  
  Since amylin is highly insoluble, and even toxic to   
pancreatic beta cells because of deposition of fibrillary   
proteins, an aqueous, non-aggregating form of amylin was  
established by replacing three amino acid residues. This   
form of amylin was found to be effective in reducing blood  
glucose level when given subcutaneously [7].  
  Pramlintide acetate, a soluble amylin analogue, marketed 
as Symlin
®, is used as a supplement to insulin in the treat- 
ment of type 1 diabetes. For example, co-administration of 
amylin analogue with insulin to a small cohort of adolescent 
with type 1 diabetes induced a larger reduction in pro- 
prandial hyperglycemia, with a concomitant reduction in the 
level of glucagon when compared to insulin monotherapy [8, 
9]. The actions of amylin and its analogues appear to be   
synergistic to insulin, with which it is co-released from insu- 
lin-producing beta cells after a meal. The positive effect of Amylin and Diabetes Mellitus  The Open Medicinal Chemistry Journal, 2011, Vol. 5    79 
pramlintide in the treatment of diabetes was acknowledged 
by an FDA (Food and Drug Administration) approval in 
March 2005. 
  Pramlintide, given subcutaneously at a dose of 30 g per 
meal, significantly reduced
 body weight, HbA1c values and 
even the dosage of insulin [10].
  
  A moderate body weight loss can also be achieved in 
obese patients with or without diabetes [11]. A major side 
effect of pramlintide is nausea [12] and vomiting due to a 
possible excitation of the area postrema [13] in the medulla 
oblongata 
BIOLOGICAL ACTIONS OF NATIVE AMYLIN AND 
AMYLIN ANALOGUES 
Native Amylin 
  Native human amylin can form fibrils in vitro and has the 
ability to induce apoptosis in cultured pancreatic beta cells 
[6]. However, some reports have shown that even the non-
fibril form of human amylin (1-19 residues of human 
amylin) is noxious to the beta cells of the pancreas. This 
non-fibrillary fragment is capable of membrane destruction 
at low concentrations [5, 14]. The ability of amylin to de-
stroy membranes has been shown by several methods includ-
ing NMR spectroscopy. Amylin is related to calcitonin and 
calcitonin-gene related peptide, messenger proteins which 
play a role in the regulation of several metabolic functions 
[15].  
Effects of Amylin Analogue 
  Amylin analogues such as pramlintide function together 
with insulin in the control of blood glucose levels. It also 
slows rapid emptying of the stomach [16]. 
Gastrointestinal Tract 
  Amylin analogues have been shown to reduce food in-
take by slowing of gastric emptying. Other studies also 
showed that it reduces the release of several digestive en-
zymes and bile acid. These properties play a role in the abil-
ity of amylin to delay the appearance of nutrients in the cir-
culation [15], and eventually, maintain glycemic control. 
  In addition, amylin analogues inhibit the production of 
glucagon, which is involved in the regulation of glu-
coneogenesis [17]. Reduction in glucagon secretion results in 
lower hepatic glucose production [18] from the liver. This 
effect may contribute to the reduction in the insulin dosage 
required to maintain euglycemia [19, 20]. 
Skeletal Muscle  
  Amylin has been reported to oppose the metabolic ac-
tions of insulin in skeletal muscle cells [16]. However, the 
role of its skeletal muscle action on the maintenance of gly-
cemic control is not clear. 
 
 
Fig. (1). Shows the amino acid sequence of amylin with cystine bond at position 2 and 7. The disulfide bond must be intact in order for 
amylin to be biologically active. 
 
Fig. (2). Amino acid sequence of the amylin analogue, pramlintide: Note the cystine bond at 2 and 7 positions. The disulfide bond must be 
intact in order for amylin analogues to be biologically active. The amino acids at positions 25, 28 and 29 have been replaced by proline (ar-
rows).  80    The Open Medicinal Chemistry Journal, 2011, Vol. 5  Adeghate and Kalász 
Food Intake 
  Peripherally administered amylin analogue, induced an-
orectic effect through a direct action on the area postrema 
and/or nucleus tractus solitarius. Amylin analogue also in-
hibits ghrelin release, an orexigenic peptide [18, 21].  
RECEPTORS OF AMYLIN 
  More than six types of amylin receptors AMY1(a), 
AMY2(a), AMY3(a), AMY1(b) AMY2(b) and AMY3(b) 
have been identified. These receptors have two units, a calci-
tonin core surrounded by a receptor activity modifying pro-
tein [22]. The receptor activity modifying proteins are di-
vided into 3 classes of proteins that traverse the plasma 
membrane [23]. 
  AMY1 receptor displays a high affinity for salmon calci-
tonin, amylin and calcitonin-gene-related peptide but a lower 
affinity for mammalian calcitonin [24]. The affinity of 
amylin2 and amylin3 receptors for calcitonin and amylin is 
similar but lower for calcitonin-gene-related peptide. 
  Amylin binding sites have been localized to several cir-
cumventricular organs, such as the subfornical organ, or-
ganum vasculosum lateralis terminalis and the area postrema 
in the medulla oblongata. These areas are outside of the 
blood brain barrier, indicating that they will respond to the 
level of pancreatic beta cell derived amylin [25]  
METABOLISM OF AMYLIN 
  The amylin produced in pancreatic beta cell alongside 
insulin is eventually excreted by the kidney. Amylin is de-
graded by insulin-degrading enzyme, a Zn
2+-rich metallopro-
tease, which also takes part in the elimination of insulin [26, 
27]. Absence of insulin-degrading enzyme in rodents induces 
glucose intolerance and cerebral accumulation of amyloid 
beta, whereas effective insulin-degrading enzyme activity 
reduces accumulation of amyloid. 
CONCLUSION 
  Amylin or diabetes-associated peptide, is co-secreted 
with insulin in the islet of Langerhans of diabetic patients in 
approximately 1:100 amylin: insulin ratio. The soluble form 
of amylin (e.g. pramlintide) is used as a supplement to insu-
lin in the treatment of type 1 diabetes. The actions of amylin 
analogues appear to be synergistic to that of insulin and can 
significantly reduce
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